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Abstract
This review focuses on the role of Aβ in AD pathogenesis in Down syndrome and current 
approaches for imaging Aβ in vivo. We will describe how Aβ deposits with age, the 
posttranslational modifications that can occur, and detection in biofluids. Three unique case 
studies describing partial trisomy 21 cases without APP triplication, and the occurrences of low 
level mosaic trisomy 21 in an early onset AD patient are presented. Brain imaging for Aβ includes 
those by positron emission tomography and ligands (Pittsburgh Compound B, Florbetapir, and 
FDDNP) that bind Aβ have been published and are summarized here. In combination, we have 
learned a great deal about Aβ in DS in terms of characterizing age of onset of this pathology and it 
is exciting to note that there is a clinical trial in DS targeting Aβ that may lead to clinical benefits.
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Introduction
Improved medical care for people with Down syndrome (DS) has led to a significant 
extension in lifespan and improved quality of life [1–3]. However, as people with DS reach 
their 40’s and 50’s, they are vulnerable to the development of Alzheimer disease (AD). 
Increased frequency of AD in DS may be related to two key factors: (1) aging, which is a 
risk factor for AD in the general population and; (2) trisomy in genes associated with AD, 
particularly the APP gene.
AD was first described by Alois Alzheimer in 1901 (see [4] for an excellent review). We 
have since learned that a key protein engaged in AD pathogenesis is beta-amyloid (Aβ). One 
of the current working hypotheses is that Aβ is a critical initiator of AD [5, 6].
Although this original hypothesis has been revised over time, due in part to the outcomes of 
recent clinical trials in AD targeting Aβ leading to little improvement in cognition[7], it is 
still considered a major contributor in the disease [8]. This review discusses the more recent 
developments regarding the role of Aβ in DS both at a molecular level and through 
neuroimaging as several reviews on both of these topics have been published elsewhere [9–
11].
APP and Chromosome 21
Aβ is produced from a longer amyloid precursor protein (APP) [12, 13], which is present on 
chromosome 21 and thus triplicated in DS [14, 15](Figure 1). It is interesting to note that 
one of the first descriptions of the biochemical properties of Aβ were from samples isolated 
from DS brain [16, 17]. In the nonamyloidogenic processing pathway, APP is first cleaved 
by α-secretase to form sAPPα and subsequently cleaved by γ-secretase to produce p3 and 
AICD (APP intracellular domain). This form of APP processing prevents the production of 
Aβ. However, in the amyloidogenic pathway, APP is first cleaved first by β-secretase to 
produce sAPPβ followed by γ-secretase cleavage yielding Aβ and AICD. The β-secretase 
enzyme has been identified as beta-site APP cleaving enzyme or BACE1 [18] and γ-
secretase consists of a complex that includes presenilin 1, nicastrin, PEN 2 and APH-1 [19].
In DS, the levels of brain Aβ are significantly higher when compared to controls at young 
ages [20] and Aβ increases exponentially with age [21, 22] after 40 years. Increasing age-
dependent Aβ in DS could be hypothesized as due to increasing APP production with age, 
increased β- or γ-secretase activity or reduced degradation (discussed later). In an autopsy 
study of 36 cases with DS, α-secretase activity appears to be relatively stable except in cases 
over 40 years of age who show a decline [22]. In contrast, studies of β-secretase activity 
show an increase with age [22] or show modest increases in protein level [23]. Further, total 
APP levels do not appear to change with age despite being higher in DS overall, suggesting 
that APP overexpression may be the primary driver of Aβ plaque accumulation [24, 25].
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A protein homologous to BACE 1, BACE2, can also cleave APP at the β-secretase site [26]. 
BACE-2 is also located on chromosome 21 and may potentially contribute to increased Aβ 
production in DS. In DS fetal tissue, BACE-2 RNA levels are significantly higher relative to 
controls [27]. In addition, in cultured fibroblasts from adults with DS, BACE-2 mRNA (i.e. 
protein expression) was 2.6 fold higher than normal controls. In 13 individuals with DS 
ranging in age from 27 weeks to 37 years, frontal cortex BACE-2 immunoreactivity was 
observed only in neurons of adults with DS and AD. BACE-2 immunoreactivity was not 
observed in younger individuals [28]. However, several studies comparing DS brain to 
similarly aged control brains do not find higher levels of BACE2 protein overall [24, 29]. 
Similarly, no differences in DS as compared to controls was observed for BACE2 in the 
intracellular compartment [27]. It is therefore possible that despite increased RNA for 
BACE2 in DS, there may be posttranscriptional regulatory mechanisms that lead to normal 
levels of BACE 2 or that increase the degradation of this enzyme [25]. Thus, APP 
overexpression and production of Aβ may be the primary driver of accumulation with age in 
DS [24, 25].
Soluble Aβ and oligomers in DS
Once Aβ is cleaved from APP it appears in soluble forms that can be detected either within 
neurons or in the extracellular space. Higher levels of soluble Aβ are observed in DS fetal 
tissue relative to tissue from controls [20]. Aβ can assemble into oligomers, protofibrils and 
Aβ-derived diffusible ligands (ADDLs)[30, 31](Figure 2). Importantly, Aβ oligomers cause 
neuronal dysfunction prior to overt neuron loss [32]. Both biochemical and 
immunohistochemical experiments reveal significant amounts of oligomeric Aβ in the AD 
brain [33–35].
In DS frontal cortex, the amount of soluble Aβ40 and Aβ42 is higher in DS relative to 
controls [36, 37]. Interestingly, phosphate buffered saline (PBS) extracted soluble Aβ40 in 
the frontal cortex increases in an exponential function with age in DS, particularly after age 
40 years [21]. However, soluble Aβ42 declines with increasing age but with a parallel 
increase in insoluble Aβ42 suggesting sequestration into plaques [21]. PBS soluble Aβ40/42 
was also not different between DS and control cases in a study by Miners et al.[23]. Water 
soluble Aβ also appears to include modifications to N-terminal glutamates [38].
Oligomeric Aβ also accumulates exponentially after the age of 40 years [21]. Further, 
increasing amounts of oligomeric Aβ in DS frontal cortex is associated with lower 
synaptophysin protein levels, suggesting impaired synaptic function [39]. Soluble and 
insoluble Aβ fibrils are also present in higher levels in aged DS cases with AD 
neuropathology compared to similarly aged control cases [40]. Thus, oligomeric Aβ may 
play a critical role in causing neuron dysfunction during both development and aging in DS. 
Indeed, a recent study in the Ts65Dn mouse using environmental enrichment, led to reduced 
hippocampal oligomers and improved cognition [41].
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Intracellular Aβ in DS
Although a large amount of Aβ exists in a soluble form, insoluble deposits also begin to 
progressively form over time. However, the subcellular location for these events is less well 
understood [42], particularly in DS, which has been discussed in a previous review and is 
updated here [10]. Gyure et al (2001) report intracellular Aβ1-40 but not Aβ1-42 [43]. In 
contrast, other studies report intracellular Aβ1-42 but not Aβ1-40 [44, 45], which in one 
study was clearly distinguished from intracellular APP immunoreactivity [44]. A report by 
Hirayama et al. found neither Aβ1-40 nor Aβ1-42 but observed intracellular Aβ1-43 [46]. 
Each length of Aβ has different properties. Aβ1-40 is more rapidly degraded within 
lysosomes than the longer, more toxic Aβ1-42/43 [47, 48]. The reasons for observations of 
different length Aβ species in intracellular deposits in each of these studies may therefore be 
due in part to technical differences.
A common observation in the majority of the studies of intracellular Aβ in DS is the early 
age of onset; both infants and children with DS accumulate intracellular Aβ. In addition, 
intracellular Aβ is consistently observed prior to the accumulation of extracellular Aβ 
deposits [44], which parallels reports in transgenic mouse models of AD [49, 50]. These 
findings suggest that prior to extracellular Aβ deposition there is an accumulation of 
intracellular Aβ within neurons in DS at a much earlier age than in the general population. 
Thus, intracellular Aβ accumulation may be important in the developmental course of DS 
and occurs prior to and contributes to age-associated extracellular Aβ deposition. The 
accumulation of neuronal Aβ may be associated with caspase cleavage products leading to 
increased apoptosis [51], which in turn may partially account for observed brain atrophy and 
neuronal loss. Intracellular Aβ is localized to endosomes, intracellular organelles responsible 
for degrading and turning over proteins within cells [52, 53]. Interestingly, partially reducing 
BACE1 in the Ts2 mouse model of DS leads to a reduction in endosomal abnormalities [54] 
typically oserved in the DS brain [53]
Aβ Plaques
There is a well established literature that that Aβ accumulates within plaques in DS in an 
age dependent process [10]. Cerebral Aβ deposition occurs decades earlier in DS compared 
to AD and control brains [14]. The deposition of extracellular Aβ in diffuse plaques is 
consistent after the age of 30 years [55], although widespread diffuse Aβ42 plaques have 
also been observed in brain sections from young DS individuals under 20 years of age [10, 
56–58]. However, it is important to note that the early Aβ deposits reported by Lemere and 
colleagues were from individuals who were institutionalized [56] suggesting a possible 
environmental impact or severity of intellectual disability in DS on Aβ accumulation. It is 
also apparent that diffuse plaques precede neuritic plaques with age in the cortex.
In DS, Aβ42 diffuse plaques precede fibrillar senile plaques containing dystrophic neurites 
and the formation of neurofibrillary tangles, and Aβ42 plaques are more prevalent than 
Aβ40 plaques at all ages [56, 59]. Diffuse Aβ42 is also deposited in DS cerebellum and 
striatum in the third decade of life, but fibrillar plaques are rarely observed in these brain 
areas in the older DS brain [60], suggesting regional effects on plaque maturation. Overall, 
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senile plaques progress in the same brain regions and cortical layers as in AD, however, 
plaque density is higher in DS brain [61].
Between the ages of 30 and 40 years, neuropathology accumulates until it reaches levels 
sufficient for a diagnosis of AD in DS by age 40 years [62]. In fact, there is an exponential 
rise in Aβ plaques, and specifically insoluble (formic acid extracted) Aβ measured 
biochemically after the age of 40 years [21, 22], suggesting an acceleration phase to clinical 
and neuropathological disease development. Identifying factors engaged during this rapid 
AD pathogenesis phase in DS may provide novel targets for intervention. For example, the 
presence of an Apo E ε4 allele doubles the cerebral amyloid plaque burden and shortens life 
span in DS [63].
Post-translationally Modified Aβ
A characteristic of Aβ is that there are several amino acids that are vulnerable to 
posttranslational modifications and identifying these species provides a measure of 
biologically “older” deposits (reviewed in [9, 10]). With age, extracellular Aβ with the N-
terminus starting at Asp1 in DS is post-translationally modified by isomerization [64], 
racemization [65] and oxidation [66]. Oxidized Aβ may reflect abnormalities in redox 
homeostasis observed in DS [67] and also possibly suggests amelioration through 
uprgulation of vitagenes [68]. An N-terminally truncated form of Aβ is generated by 
degradation of the first 2 amino acids followed by cyclization of the newly formed N-
terminus by glutaminyl cyclase, resulting in degradation-resistant, highly toxic aggregates of 
pyroglutamate-3 Aβ that deposit into plaques and blood vessel walls in AD and DS brain 
[56, 69–71]. Pyroglutamate-11 Aβ, a minor species, is also detected in some plaque cores 
and vascular amyloid in DS brain [72, 73]. Unmodified Aβ1-40/42 is also elevated in DS 
brain, possibly due to the overexpression of BACE 2, a gene encoded on chromosome 21 
[73]. In addition, the APP P3 peptide, starting at the non-amyloidogenic α-secretase site 
(Aβ17leu), can be observed readily in DS brain extracts [74] and cerebellar plaques [75]. 
These modifications may reflect mechanisms of Aβ production and could potentially serve 
as possible chronobiological age markers for individual deposits and AD progression.
Cerebrovascular Aβ Pathology in DS
The contriboution of cerebrovascular disease (CVD) to AD is increasingly being recognized 
as a critical comorbidity that accelerates the age of onset of dementia and also leads to a 
faster progression of the disease [76]. Further, estimates of a mixed etiology of AD that 
includes CVD range from 5.7–45% of autopsy cases from the general population [77]. CVD 
can serve as a “second hit” necessary for clinical signs of dementia, particularly when 
significant Aβ is present in the brain [78]. DS represents a unique opportunity to study the 
cerebrovascular features of aging and AD in the context of limited systemic vascular risk 
factors (reviewed in [79]) including absence of atheroma and hypertension.
Cerebral amyloid angiopathy (CAA) is the deposition of amyloid in the walls of medium- 
and small-size leptomeningeal and cortical arteries, arterioles and, less frequently, capillaries 
and veins. CAA can lead to micro and macro hemorrhages [80]. CAA is consistently 
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observed in older individuals with DS (>55 yrs - [81–83] although study sizes include 
relatively small cohorts. CAA contains post-translationally modified Aβ [71] as described in 
plaques. There are few reports of CAA in DS being associated with hemorrhages [83–87] in 
some but not all case reports [81, 82]. Brain Aβ40 (typically associated with CAA) rises 
exponentially with age in DS [21]. The functional consequences of CAA remains an area 
rich for futher study as adults with DS represent a unique cohort to study the consequences 
of CVD co-morbidities in the absence of several cardiovascular risk factors. There are 
currently no systematic reports of CVD as a function of aging or cognition in DS. In terms 
of designing future clinical trials, characterizing the age of onset and extent of CVD in 
adults with DS will be critical given that CVD is mediated to large extent by lifestyle factors 
that are amenable to intervention such asindividuals with hypertension, high cholesterol, 
obesity or type II diabetes (reviewed in: [88]).
Enzymes involved with Aβ Degradation and Clearance in the Brain and DS
Several enzymes in the brainare involved with the degradation and clearance of Aβ. These 
Aβ clearing enzymes include insulin degrading enzyme (IDE), neprilysin, and tissue 
plasminogen activator [89–91]. In DS, two components leading to increased production of 
Aβ are present in triplicate and include APP and BACE2. However, despite life-long 
overexpression of these two proteins, full blown AD neuropathology is not consistently 
observed until after age 40 years. Thus, Aβ may be cleared or degraded in the DS brain by 
the activity of these Aβ degrading enzymes.
Neprilysin protein concentration is increased in DS and correlates with levels of insoluble 
Aβ [23]. Further, the overexpression of DRYK1a in DS [92] reduces neprilysin activity in 
DS fibroblasts [93]. Normalization of reduced neprilysin protein levels in the Ts65Dn mouse 
model of DS by environmental enrichment is associated with improved cognition [41]. 
Considering the therapeutic potential of enhancing Aβ degradation and clearance, this 
represents a major gap in our knowledge in the study of development and aging in DS. 
Studies of age-dependent changes in IDE or tissue plasminogen activator were not found 
suggesting this is an area requiring further study in DS.
Case Studies Supporting the Role of APP and Aβ in AD Pathogenesis in DS
The most common cause of DS is trisomy 21 accounting for 95% of all individuals with DS. 
However, two other causes include partial trisomy 21 (4% of people) and mosaicism (1% of 
people). There are few case studies of unique individuals with DS who are mosaic or have 
parital trisomy and thus, have varying degrees of APP overexpression. In 1998, Prasher and 
colleagues described a 78 year old female with DS who did not develop dementia and who 
did not show autopsy evidence of AD. Molecular mapping studies determined that this 
person was disomic for APP and SOD1 but trisomic for S100β [94]. Recently, Doran and 
colleagues describe a second partial trisomy case, a male who lived to 72 years of age 
without dementia [95]. This person was negative for Pittsburgh Compound B (PiB) amyloid 
imaging and at autopsy, showed little Aβ (sporadic plaques) and a Braak stage III. Genetic 
mapping of this partial trisomy case indicated that APP was present in duplicate but S100β 
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and SOD1 were triplicated. Thus, studies of people with partial trisomy 21 strongly suggest 
that the presence of APP is critically involved with the development of AD.
Another fascinating case report by Ringman and colleagues describes a 55 year old man 
with a mild intellectual delay but early onset dementia [96]. Standard karyotyping showed 
that he was 10% mosaic for chromosome 21. There have been three similar previous reports 
of people with mosaicism with varying degrees of a DS phenotype but all developed early 
onset dementia (41–52 years) [97–99]. Older people with DS also show evidence of an 
acquired low level mosaicism suggesting a loss of chromosome 21, the functional 
consequences of this observation are as yet unknown [100]. Mosaic DS case studies suggest 
that even a small increase in genetic APP load and possibly Aβ is sufficient to drive early 
onset dementia in DS.
Aβ Neuroimaging
There have been several reviews describing structural and functional neuroimaging 
outcomes in people with DS [11, 101]. For this review, we will focus on Aβ neuroimaging. 
In vivo ligands have been developed that selectively bind to Aβ and can be used in 
conjuction with positron emission tomography (PET) to visualize Aβ plaques in people 
antemortem [102–105]. Pittsburgh Compound B (PiB) [106], the first of these Aβ ligands, 
has now been used in a large number of clinical studies in patients with AD and can detect 
Aβ load early in the disease [103].
In DS, PiB PET imaging studies indicate that binding is age-dependent [107–111](Figure 3). 
In people with DS who are cognitively impaired, there is a positive correlation with the 
extent of PiB binding [107, 110]. Interestingly, the striatum is the earliest site of PiB binding 
in DS, typically observed after 35 years of age [107–109]. This finding is similar to reports 
of patients with presenilin-1 mutations [112–114]. With age, more brain regions, primarily 
cortical, show in vivo Aβ binding [107].
Similar results have been reported for other Aβ ligands including Florbetapir [115–117] and 
2-(1-[118]ethylidene) malononitrile ([(18)F]FDDNP) [118]. FDDNP also binds to tau and it 
is not possible to distinguish Aβ plaques from neurofibrillary tangles. It is interesting to 
note, however, that florbeptir and FDDNP do not show early striatal binding as reported for 
PiB, suggesting that either the various ligands have different affinity for different types of 
Aβ or that PiB binding may also indicate additional neuropathologies.
A recent report of 3 years of longitudinal study of PiB binding in nondemented people with 
DS showed that 85% of PiB negative subjects remained negative while 15% converted to 
being PiB positive [119]. Those who converted to being PiB positive tended to show a 3.7% 
increase in binding per year. (Figure 4)
PiB in DS – autopsy studies
In vivo imaging using PiB suggests that cortical binding is age dependent. In autopsy cases 
with sporadic AD, 3H-PiB and 6-CN-PiB binding in vitro has been described [112, 120–
123]. In these studies, PiB binds to Aβ40 and Aβ42 positive plaques as well as vascular Aβ. 
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Further, PiB binding was more robust in compact or cored plaques and less so with diffuse 
plaques. PiB binding also correlates with insoluble Aβ measures and with plaque loads. In 
one case that was PET imaged in life with PiB and then came to autopsy, there was a 
significant overlap in the regional distribution of the in vivo plaque binding and in vitro PiB 
binding [122].
A recent study described PiB binding in vitro in DS brain [124]. Biochemical measures of 
PiB binding in vitro using 3H-PiB was significantly associated with increasing age. After 
age 40 years in DS, 3H-PiB binding rose dramatically along with increasing individual 
variability. 3H-PiB binding correlated with the amount of Aβ42. Frontal cortex neuritic and 
cored plaques in DS brain along with extensive cerebral amyloid angiopathy (CAA) were 
positive for 6-CN-PiB. Thus, cortical PiB binding in vivo as shown by PET imaging reflects 
plaques and CAA in DS brain (Figure 5).
Summary
People with DS show age-dependent accumulations of Aβ in plaques and in CAA similar to 
that observed in sporadic AD. However, the age of onset of Aβ appears to be at least a 
decade if not more, earlier than that reported for the general population. The age-depedency 
of Aβ accumulation provides unique opportunities for targeted clinical trials in people with 
DS to slow or prevent AD as prophylactic windows can be identified based on plasma, 
neuroimaging, and clinical markers of AD processes. However, there are still several gaps 
remaining in our understanding of Aβ accumulation in DS including a lack of information 
regarding Braak amyloid staging and severity of dementia as well as the need to learn more 
about PiB binding in striatum (along with functional consequences). Autopsy studies in 
people with DS are challenging and the amount of tissue available for research from 
clinically characterized and prospectively followed people is very limited. New ligands that 
bind to tau pathology are currently being examined in DS cohorts and will provide novel and 
exciting information as to the staging of Aβ vs tau with age and links to cognition.
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Highlights
• Aging in DS is associated with early onset Alzheimer disease
• Beta-amyloid increases exponentially after 40 years of age
• Evidence from partial trisomy DS indicates overexpression of APP leads to 
AD
• PiB binding in DS is observed in striatum prior to cortex
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Figure 1. The proteolytic processing of APP
APP can be cleaved by α-, β- and γ-secretases; the cleavage sites of these proteases are 
indicated in the full-length APP shown in the center of the figure. APP can undergo 
amyloidogenic (right) or non-amyloidogenic (left) processing. In the amyloidogenic 
pathway, cleavage by β-secretase results in the formation of soluble APPβ (sAPPβ) and 
βAPP-CTF. The subsequent action of γ-secretase on βAPP-CTF releases Aβ from the 
amyloid precursor protein intracellular domain (AICD). In the non-amyloidogenic pathway, 
cleavage by α-secretase prevents the formation of Aβ; α-secretase cleaves within the Aβ 
sequence, giving rise to sAPPα and the membrane-tethered αAPP-CT, which in turn is 
cleaved by γ-secretase resulting in release of the P3 peptide and AICD. Reproduced with 
permission from Nicolas & Hassan, 2014[125].
Head et al. Page 18
Free Radic Biol Med. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Oligomer pathway
Amyloid- (A) can exist in multiple assembly states — monomers, oligomers, protofibrils 
and fibrils — and it is the ability of this peptide to form fibrils and other intermediate states 
that impart the unique pathophysiological characteristics that define Alzheimer’s disease 
pathology. Fibril formation is a complex, nucleation-dependent process. The mechanism 
driving this process, particularly in the elderly brain, is not yet known, but it appears to be 
closely related to protein misfolding. In its monomeric state, A does not appear to be 
neurotoxic. By contrast, oligomeric and protofibrillar species are considered potent blockers 
of long-term potentiation, a form of synaptic plasticity. Reproduced with permission from 
LaFerla and colleagues [126].
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Figure 3. PiB binding in DS
A schematic brain map of numbered Brodmann areas and subcortical regions of interest 
colored according to the PIB staging model, where shade 1 denotes the area affected first 
(i.e. the striatum) and shade 9 the area affected latest (the amygdala). Abbreviations: thal, 
thalamus; amy, amygdala; PIB, Pittsburgh compound–B. Reproduced from Annus et al., 
2016 (Creative Commons Attribution License (CC BY)[107].
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Figure 4. Longitudinal plots of mean PiB SUVR against age
with the PiB positivity thresholds in each ROI shown as the dotted line. Each line represents 
a nondemented adult with DS. The PiB(-) group (N = 35) is shown in blue, the PiB converter 
group (N = 6) is shown in green, and the PiB(+) group (N = 11) is shown in red. 
Abbreviations: PiB, Pittsburgh compound B; ROI, region of interest; SUVR, standard uptake 
value ratio. Reproduced from Lao et al., 2017(open access article CC BY-NC-ND)[119].
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Figure 5. PiB binding to CAA and vascular pathology in DS
(A) 6-CN-PiB (blue) binds to CAA and to plaques (green thioflavine S staining) in the brain 
of a 41 year old female with DS and AD. CVD in two DS volunteers in the University of 
Kentucky aging study, 57 and 59 year old males imaged with T2* (B and D) and FLAIR (C 
and E) sequences showing that microbleeds are present in older people with DS and may be 
due to CAA (arrows distinguish edema and hemosiderin positive microbleeds (arrows)).
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